Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00000898 · ClinicalTrials.gov registry record · NA

The Effects of Staggered Dosing on Interactions Between Paired Combinations of Nelfinavir, Ritonavir, and Saquinavir

A NA study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
NA
Development phase
18
Enrollment target
4
Study locations

NCT00000898 is a NA study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 18 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (96% lower). The trial reports 4 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00000898, a NA study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
NA
Development phase
18 participants
Enrollment target
4
Study locations

Study Summary

The purpose of this study is to see if staggering doses of nelfinavir, ritonavir, and saquinavir has any effect on the interactions between these drugs.

Conditions Studied

Interventions

  • DRUG Ritonavir
  • DRUG Nelfinavir mesylate
  • DRUG Saquinavir

Study Locations (4)

California

  • San Francisco Gen Hosp - San Francisco
  • Univ of California/ San Francisco / Dept of Medicine - San Francisco
  • Stanford Univ Med Ctr - Stanford

Maryland

  • Johns Hopkins Hosp - Baltimore

Trial Details

FieldValue
Enrollment Target 18 participants
Est. Completion 2000-05
Phase NA

What the Registry Record Tells You About NCT00000898

The ClinicalTrials.gov registry entry for NCT00000898 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (96% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 3 interventions - of which Ritonavir is the first listed.

NCT00000898 reports 4 study locations spanning 2 distinct geographic areas - top geographies include California, Maryland.

Frequently Asked Questions

What is clinical trial NCT00000898 about?

NCT00000898 is a clinical study titled "The Effects of Staggered Dosing on Interactions Between Paired Combinations of Nelfinavir, Ritonavir, and Saquinavir". The purpose of this study is to see if staggering doses of nelfinavir, ritonavir, and saquinavir has any effect on the interactions between these drugs.

What is the current status of trial NCT00000898?

This trial is currently completed. It is a NA study. The enrollment target is 18 participants. Estimated completion is 2000-05.

What conditions does trial NCT00000898 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00000898?

The interventions under investigation include: Ritonavir (DRUG), Nelfinavir mesylate (DRUG), Saquinavir (DRUG).

Who is sponsoring clinical trial NCT00000898?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00000898 being conducted?

This trial has 4 study locations across California, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.